Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins sold 386,240 shares at $22.01 per share on July 2, 2026, for a total of $8.5 million. The sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2026, and Robins still directly holds 1,019,658 shares worth approximately $21.61 million. The stock had returned 85% over the prior year as of the transaction date, and the company recently reported first-quarter revenue up 35% to $70.9 million, driven by its clonoSEQ MRD test, while narrowing its net loss to $20 million.
Adaptive Biotechnologies CorpCSO sold $8.5M in stock under a 10b5-1 plan, but the sale is pre-planned and not necessarily a negative signal; stock had 85% run and company reported strong revenue growth.